全文获取类型
收费全文 | 1489篇 |
免费 | 94篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 47篇 |
妇产科学 | 29篇 |
基础医学 | 182篇 |
口腔科学 | 24篇 |
临床医学 | 144篇 |
内科学 | 280篇 |
皮肤病学 | 23篇 |
神经病学 | 261篇 |
特种医学 | 66篇 |
外科学 | 118篇 |
综合类 | 16篇 |
预防医学 | 112篇 |
眼科学 | 73篇 |
药学 | 127篇 |
中国医学 | 3篇 |
肿瘤学 | 82篇 |
出版年
2023年 | 6篇 |
2022年 | 21篇 |
2021年 | 34篇 |
2020年 | 19篇 |
2019年 | 32篇 |
2018年 | 38篇 |
2017年 | 35篇 |
2016年 | 27篇 |
2015年 | 30篇 |
2014年 | 43篇 |
2013年 | 64篇 |
2012年 | 67篇 |
2011年 | 90篇 |
2010年 | 51篇 |
2009年 | 45篇 |
2008年 | 99篇 |
2007年 | 87篇 |
2006年 | 89篇 |
2005年 | 100篇 |
2004年 | 88篇 |
2003年 | 93篇 |
2002年 | 70篇 |
2001年 | 9篇 |
2000年 | 11篇 |
1999年 | 7篇 |
1998年 | 9篇 |
1997年 | 16篇 |
1996年 | 12篇 |
1995年 | 10篇 |
1994年 | 10篇 |
1993年 | 12篇 |
1992年 | 11篇 |
1991年 | 7篇 |
1989年 | 5篇 |
1988年 | 6篇 |
1986年 | 6篇 |
1985年 | 10篇 |
1984年 | 12篇 |
1983年 | 12篇 |
1982年 | 14篇 |
1981年 | 17篇 |
1980年 | 11篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 10篇 |
1976年 | 16篇 |
1974年 | 5篇 |
1972年 | 8篇 |
1963年 | 6篇 |
1961年 | 6篇 |
排序方式: 共有1587条查询结果,搜索用时 0 毫秒
21.
Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. 总被引:5,自引:0,他引:5
Alexander Kuo Jules L Dienstag Raymond T Chung 《Clinical gastroenterology and hepatology》2004,2(3):266-272
BACKGROUND & AIMS: Lamivudine resistance occurs in patients with chronic hepatitis B at rates of 16%-32% after 1 year and 49% after 3 years. Adefovir dipivoxil, a nucleotide analogue recently approved by the Food and Drug Administration for the treatment of chronic hepatitis B, is effective against hepatitis B virus (HBV) but has been associated with renal toxicity at high doses. Tenofovir disoproxil fumarate is another nucleotide analogue with demonstrated antiviral activity against both wild-type and lamivudine-resistant HBV. Tenofovir, at its licensed dose, has not been associated with renal dysfunction. METHODS: We describe a series of 9 patients with lamivudine-resistant hepatitis B treated with tenofovir, 300 mg, once daily before the availability of adefovir. Levels of HBV DNA, alanine aminotransferase (ALT), hepatitis B e antigen (HBeAg), and antibody to HBeAg (anti-HBe) were monitored. RESULTS: The addition of tenofovir to the existing regimen of lamivudine resulted in a median decline of 4.5 log(10) copies/mL in HBV DNA levels (range, 3.2-6.3 log(10) copies/mL) after a median treatment duration of 12 months (range, 6-16 mo). HBeAg seroconversion was observed in 2 patients, with a third patient undergoing HBeAg loss while remaining anti-HBe negative. In 4 of 7 patients with elevated ALT levels at baseline, ALT levels normalized. No significant adverse events were encountered during treatment. CONCLUSIONS: In patients with lamivudine-resistant hepatitis B, treatment with tenofovir is well tolerated and results in significant virological, serological, and biochemical improvements on par with those seen with high-dose adefovir (30 mg/day) therapy, without the complication of renal toxicity. 相似文献
22.
Durability of serologic response after lamivudine treatment of chronic hepatitis B 总被引:38,自引:0,他引:38
Dienstag JL Cianciara J Karayalcin S Kowdley KV Willems B Plisek S Woessner M Gardner S Schiff E 《Hepatology (Baltimore, Md.)》2003,37(4):748-755
Forty subjects with chronic hepatitis B and hepatitis B e antigen (HBeAg) seroconversion following lamivudine therapy in previous trials were monitored after treatment to assess the durability of serologic responses. Patient follow-up began a median of 4.3 months after completion of therapy in previous trials. At months 2, 4, 6, 9, and 12 of year 1, and every 6 months thereafter, we tested for HBeAg and hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV) DNA, and alanine aminotransferase (ALT). After a median (range) of 36.6 (4.8-45.6) months of follow-up monitoring, HBeAg seroconversion was demonstrated at the last visit by 77% (30 of 39) of patients. In a post hoc analysis of a slightly different population of all 65 patients with HBeAg seroconversion in previous trials, the 3-year durability of HBeAg seroconversion measured from the time immediately after discontinuing lamivudine therapy was 64%. Nine (9 of 40, 23%) patients were HBsAg negative at the last assessment. Seventy-four percent (17 of 23) of patients with baseline undetectable HBV DNA and normal ALT maintained these responses at the last visit. Eight patients (8 of 40, 20%) initiated retreatment for reappearance of HBV markers, and 7 showed biochemical and/or virologic improvement (including regained HBeAg seroconversion in 2). No safety issues of concern emerged. In conclusion, most HBeAg responses achieved during lamivudine therapy were durable, and most responders experienced prolonged clinical benefit after HBeAg seroconversion and subsequent discontinuation of lamivudine. Lamivudine retreatment for reappearance of hepatitis B markers can achieve resumption of viral suppression. 相似文献
23.
Perrillo RP Lai CL Liaw YF Dienstag JL Schiff ER Schalm SW Heathcote EJ Brown NA Atkins M Woessner M Gardner SD 《Hepatology (Baltimore, Md.)》2002,36(1):186-194
Elevated alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likelihood of hepatitis B e antigen (HBeAg) loss in patients with chronic hepatitis B treated with interferon. Predictors of HBeAg loss in patients treated with lamivudine are not known. The objective of this analysis of 4 lamivudine-controlled Phase III trials was to determine patient-dependent or laboratory variables that predict HBeAg loss. Predictors of HBeAg loss in patients treated with interferon, lamivudine plus interferon, or placebo are also described. A total of 805 adults with chronic hepatitis B were treated either with lamivudine (n = 406), matching placebo (n = 196), interferon (n = 68), or the combination of lamivudine plus interferon (n = 135). Demographic and baseline disease characteristics were used in stepwise multivariate analyses to identify features that were predictive of lamivudine-induced HBeAg loss. HBeAg loss correlated with increased pretreatment ALT levels in all groups. The rate of HBeAg loss was highest among patients with pretreatment ALT levels greater than 5 times the upper limit of normal (ULN) and was most pronounced in the lamivudine group (56%). Multivariate modeling indicated that elevated baseline ALT levels (P <.001) and histologic activity index (HAI) score (P <.001) were important predictors of HBeAg loss in response to lamivudine. The effect of pretreatment ALT levels on HBeAg loss was similar for Asians and Caucasians. In conclusion, elevated pretreatment ALT levels and/or active histologic disease were the most important predictors of lamivudine-induced HBeAg loss. Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels. 相似文献
24.
25.
26.
27.
28.
29.
30.